KEY POINTS
-
Moderna is expanding its Norwood, Massachusetts, facility with a $140 million investment, aiming to complete its end-to-end domestic mRNA production capabilities by 2027.
-
The project will create construction and skilled biomanufacturing jobs, contributing to the regional economy and supporting the life sciences and pharmaceutical industries.
-
By consolidating its mRNA production domestically, Moderna aims to enhance its supply chain resilience, supporting both commercial and clinical needs while advancing its vaccine pipeline.
Vaccine manufacturer Moderna announced an expansion of its U.S. manufacturing footprint, investing more than $140 million in its Moderna Technology Center (MTC) located in Norwood, Massachusetts.
“Through this strategic onshoring, Moderna will now operate full end-to-end manufacturing for its mRNA medicines in the US,” the company said in a statement.
Strengthening Its US Manufacturing and Supply Chain
Construction started at the Norwood site to accommodate the new manufacturing capabilities. The project is a key component of Moderna’s strategy to strengthen its domestic supply chain and manufacturing infrastructure, it said in a press release on November 19, 2025.
This strategic project, once built and operational, will complete Moderna’s fully integrated, end-to-end mRNA production capabilities domestically.
“By onshoring Drug Product manufacturing to our campus in Norwood, Massachusetts, we have completed the full manufacturing loop under one roof in the U.S.,” said Stéphane Bancel, Chief Executive Officer of Moderna.
The company is targeting completion for the first half of 2027.
Impact on Construction and Manufacturing Labor
This expansion is poised to have an impact on the local construction and biomanufacturing sectors. The investment will create hundreds of highly skilled biomanufacturing jobs in the community, providing a boost to the regional economy.
For the construction industry, this project represents an opportunity within the specialty life sciences and pharmaceutical facility sector.
Chief Executive Officer Bancel added, “As an American company committed to building and producing in America, we are proud to strengthen our domestic footprint while bringing meaningful new jobs to the community.”
The project highlights Moderna’s continued commitment to investing in its U.S.-based infrastructure. By consolidating its entire mRNA production process domestically, from raw materials to finished product, the company strengthens its ability to support both its commercial and clinical supply needs.
Moderna, based in Cambridge, Massachusetts, specializes in mRNA therapeutics, using messenger RNA to trigger immune responses. Known for its COVID-19 vaccine, Spikevax, and RSV vaccine, mResvia, the company has a pipeline of 44 vaccine and treatment candidates targeting diseases like influenza, HIV, and cancer.
Stay Connected
Stay connected with ConstructConnect News, your source for construction economy insights, market trends, and project news.
About ConstructConnect
At ConstructConnect, our software solutions provide the information that construction professionals need to start every project on a solid foundation. For more than 100 years, our keen insights and market intelligence have empowered commercial firms, building product manufacturers, trade contractors, and architects to make data-driven decisions, streamline preconstruction workflows, and maximize their productivity. Our newest offerings—including our comprehensive, AI-assisted software—help our clients find, bid on, and win more projects.
ConstructConnect operates as a business unit of Roper Technologies (Nasdaq: ROP), a constituent of the Nasdaq 100, S&P 500, and Fortune 1000.
For more information, visit constructconnect.com
